Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO Inc. and is encouraging investors who suffered losses to discuss their legal options [1] Group 1 - The investigation pertains to securities purchased or acquired in REGENXBIO between February 9, 2022, and January 27, 2026 [1] - There is a deadline of April 14, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against REGENXBIO [1]

Group 1: AI Infrastructure Market Overview - AI infrastructure stocks have experienced significant growth due to massive investments in data centers, benefiting various sectors including chip design, foundries, power companies, and server manufacturers [1][2] - The demand for fast networking and high bandwidths in AI data centers has positively impacted networking component manufacturers [2] Group 2: Ciena's Performance and Outlook - Ciena's stock has risen by 47% in 2026, continuing its strong performance from 2025, driven by increased AI data center spending [4] - Ciena anticipates a growth rate of 24% in fiscal 2026, an improvement from the previous year's 19% revenue growth, supported by a record backlog of $5 billion [5] - In the previous year, Ciena received $7.8 billion in orders, surpassing its annual revenue of $4.8 billion, indicating strong demand that is expected to continue into 2027 and beyond [6]

SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of PayPal Holdings, Inc. (NASDAQ: PYPL) common stock between February 25, 2025 and February 2, 2026, inclusive (the “Class Period”), have until April 20, 2026 to seek appointment as lead plaintiff of the PayPal class action lawsuit. Captioned Goodman v. PayPal Holdings, Inc., No. 26-cv-01381 (N.D. Cal.), the PayPal class action lawsuit charges PayPal as well as certain of PayPal’s top current ...

Northpointe Bancshares, Inc. Announces Appointment of Rodney E. Hood to its Board of DirectorsFeb 27, 2026 9:20 AM Eastern Standard Time# Northpointe Bancshares, Inc. Announces Appointment of Rodney E. Hood to its Board of DirectorsShare---GRAND RAPIDS, Mich.--([BUSINESS WIRE])--Northpointe Bancshares, Inc. (NYSE: NPB) (the "Company†), announced today that the Honorable Rodney E. Hood has been appointed to the Board of Directors of the Company and its subsidiary, Northpointe Bank, effective February 27, 2 ...

Circle reported earnings earlier this week, beating expectations, and the shares have had quite the run this week to discuss the report and developments since its IPO last year. We want to welcome in our next guest. That's Jeremy Fox, CFO of Circle.Jeremy, thank you so much for joining us. Uh, great quarter. I mean, the EPS number strong, much stronger than expected, sizable beat there.Revenue better than expected, 770 million. Take us through just some of the highlights really quickly. >> Good morning, Dia ...

Core Insights - FormFactor, Inc. (FORM) has demonstrated strong stock performance, increasing by 75% year-to-date (YTD) [1] Group 1: Company Performance - The stock has been on a strong upward trend since reporting Q4 2025 earnings on February 4th [1]

Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies [Accessibility Statement] Skip NavigationSpinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platformLead candidates ATR 1072 and ATR 1086 expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, respectivelySAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ...

Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Delta Resources Limited (TSXV: DLTA) (OTC Pink: DTARF) (FSE: 6GO1) ("Delta" or "the Company") is pleased to report the preliminary interpretation from the 2024-25 till survey conducted by IOS Géosciences in the I-Zone sector, located approximately 18 kilometres southwest of the Eureka Gold Deposit and about 60 kilometres west of Thunder Bay, Ontario. The till survey, completed in the fall of 2025 (see September 17, 2025 news release), has identified ...

This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results were reported across multiple therapeutic areas, including radiographic and non-radiographic axial spondyloarthritis, microcystic lymphatic malformations, pulmonary arterial hypertension, and obesity. Here's a closer look at the details. FDA Approvals & Rejections Armata Pharma Secures FDA QIDP Designation for AP-SA02 Armata Pharmaceuticals, ...

Group 1 - Netflix stock is poised for a 50% surge, potentially rising from $90 to $135, following its decision to walk away from an $83 billion offer for Warner Bros. Discovery [1] - Analysts have upgraded Netflix's stock, with Wells Fargo raising its target price by 23% and Pivotal Research Group increasing it by 19%, citing strong subscriber growth and compelling entertainment value [1] - In Q2, Netflix reported a 16% year-over-year revenue increase to $11.1 billion, with diluted EPS rising from $4.88 to $7.19 and operating margins growing from 27.2% to 31.5% [1] Group 2 - Netflix's revenue increased by 18% year-over-year in Q4, crossing the 325 million paid memberships milestone, with operating income rising by 30% [1] - The company is recognized as the leading streaming service in the U.S. and is expected to maintain its momentum without significant changes in its operational strategy [1] - Netflix's advertising revenue is growing, indicating a shift beyond its traditional subscriber-supported model [1]